Book Text

REFERENCES

151. Reissell E, Orko R, Maunuksela EL, et al: Predictability of difficult laryngoscopy in patients with long-term diabetes mellitus. Anaesthesia 45:1024–1027, 1990.

152. Warner ME, Contreras MG, Warner MA, et al: Diabetes mellitus and difficult laryngoscopy in renal and pancreatic transplant patients. Anesth Analg 86:516–519, 1998.

153. Kirvela M, Scheinin M, Lindgren L: Haemodynamic and catecholamine responses to induction of anaesthesia and tracheal intubation in diabetic and non-diabetic uraemic patients. Br J Anaesth 74:60–65, 1995.

154. Sieber FE: The neurologic implications of diabetic hyperglycemia during surgical procedures at increased risk for brain ischemia. J Clin Anesth 9:334–340, 1997.

155. Hemmerling TM, Schmid MC, Schmidt J, et al: Comparison of a continuous glucose-insulin-potassium infusion versus intermittent bolus application of insulin on perioperative glucose control and hormone status in insulin-treated type 2 diabetics. J Clin Anesth 13:293–300, 2001.

156. Roberts JP, Brown RS Jr, Edwards EB, et al: Liver and intestine transplantation. Am J Transplant 3(Suppl 4):78–90, 2003.

157. Kim FJ, Ratner LE, Kavoussi LR: Renal transplantation: Laparoscopic live donor nephrectomy. Urol Clin North Am 27:777–785, 2000.

158. Kim WR: The burden of hepatitis C in the United States. Hepatology 36(5 Suppl):S30–S34, 2002.

159. Wiesner RH, Rakela J, Ishitani MB, et al: Recent advances in liver transplantation. Mayo Clin Proc 78:197–210, 2003.

160. Davis CL, Gonwa TA, Wilkinson AH: Identification of patients best suited for combined liver-kidney transplantation: Part II. Liver Transpl 8:193–211, 2002.

161. Rydberg L: ABO-incompatibility in solid organ transplantation. Transfus Med 11:325–342, 2001.

162. Bjoro K, Ericzon BG, Kirkegaard P, et al: Highly urgent liver transplantation: Possible impact of donor-recipient ABO matching on the outcome after transplantation. Transplantation 75:347–353, 2003.

163. Vaquero J, Blei AT: Etiology and management of fulminant hepatic failure. Curr Gastroenterol Rep 5:39–47, 2003.

164. Fujiwara K, Mochida S: Indications and criteria for liver transplantation for fulminant hepatic failure. J Gastroenterol 37(Suppl 13):74–77, 2002.

165. Wiesner RH, McDiarmid SV, Kamath PS, et al: MELD and PELD: Application of survival models to liver allocation. Liver Transpl 7:567–580, 2001.

166. Freeman RB Jr, Wiesner RH, Harper A, et al: The new liver allocation system: Moving toward evidence-based transplantation policy. Liver Transpl 8:851–858, 2002.

167. Figueiredo F, Dickson ER, Pasha T, et al: Impact of nutritional status on outcomes after liver transplantation. Transplantation 70:1347–1352, 2000.

168. Freeman RB, Harper AM, Edwards EB: Redrawing organ distribution boundaries: Results of a computer-simulated analysis for liver transplantation. Liver Transpl 8:659–666, 2002.

169. Roberts JP: Prioritization of patients with liver cancer within the MELD system. Liver Transpl 8:329–330, 2002.

170. Saab S, Wang V, Ibrahim AB, et al: MELD score predicts 1-year patient survival post-orthotopic liver transplantation. Liver Transpl 9:473–476, 2003.

171. Wongcharatrawee S, Groszmann RJ: Diagnosing portal hypertension. Baillieres Best Pract Res Clin Gastroenterol 14:881–894, 2000.

172. Groszmann RJ: Hyperdynamic circulation of liver disease 40 years later: Pathophysiology and clinical consequences, Hepatology 20:1359–1363, 1994.

173. Cardenas A, Gines P: Pathogenesis and treatment of fluid and electrolyte imbalance in cirrhosis. Semin Nephrol 21:308–316, 2001.

174. Merritt WT: Metabolism and liver transplantation: Review of perioperative issues. Liver Transpl 6(4 Suppl 1):S76–S84, 2000.

175. Blei AT: Brain edema and portal-systemic encephalopathy. Liver Transpl 6(4 Suppl 1):S14–S20, 2000.

176. Abou-Assi S, Vlahcevic ZR: Hepatic encephalopathy. Metabolic consequence of cirrhosis often is reversible. Postgrad Med 109:52–54, 57–60, 63–65 passim, 2001.

177. Bass NM: Monitoring and treatment of intracranial hypertension. Liver Transpl 6(4 Suppl 1):S21–S26, 2000.

178. Sorkine P, Ben Abraham R, Szold O, et al: Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med 29:1332–1336, 2001.

179. Mitzner SR, Stange J, Peszynski P, et al: Extracorporeal support of the failing liver. Curr Opin Crit Care 8:171–177, 2002.

180. Sen S, Jalan R, Williams R, et al: Liver failure: Basis of benefit of therapy with the molecular adsorbents recirculating system. Int J Biochem Cell Biol 35:1306–1311, 2003.

181. Heemann U, Treichel U, Loock J, et al: Albumin dialysis in cirrhosis with superimposed acute liver injury: A prospective, controlled study, Hepatology 36(4 Pt 1):949–958, 2002.

182. Mitzner SR, Stange J, Klammt S, et al: Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial. Liver Transpl 6:277–286, 2000.

183. Sen S, Mookerjee RP, Davies NA, et al: Review article: The molecular adsorbents recirculating system (MARS) in liver failure. Aliment Pharmacol Ther 16(Suppl 5):32–38, 2002.

184. Henriksen JH, Kiszka-Kanowitz M, Bendtsen F: Review article: Volume expansion in patients with cirrhosis. Aliment Pharmacol Ther 16(Suppl 5):12–23, 2002.

185. Moller S, Henriksen JH: Cirrhotic cardiomyopathy: A pathophysiological review of circulatory dysfunction in liver disease. Heart 87:9–15, 2002.

186. Moller S, Henriksen JH: Cardiovascular dysfunction in cirrhosis. Pathophysiological evidence of a cirrhotic cardiomyopathy. Scand J Gastroenterol 36:785–794, 2001.

187. Krowka MJ: Hepatopulmonary syndrome: Recent literature (1997 to 1999) and implications for liver transplantation. Liver Transpl 6(4 Suppl 1):S31–S35, 2000.

188. Fallon MB, Abrams GA: Hepatopulmonary syndrome. Curr Gastroenterol Rep 2:40–45, 2000.

189. Aboussouan LS, Stoller JK: The hepatopulmonary syndrome. Baillieres Best Pract Res Clin Gastroenterol 14:1033–1048, 2000.

190. Budhiraja R, Hassoun PM: Portopulmonary hypertension: A tale of two circulations. Chest 123:562–576, 2003.

191. Schraufnagel DE, Kay JM: Structural and pathologic changes in the lung vasculature in chronic liver disease. Clin Chest Med 17:1–15, 1996.

2278

192. Hadengue A, Benhayoun MK, Lebrec D, et al: Pulmonary hypertension complicating portal hypertension: Prevalence and relation to splanchnic hemodynamics. Gastroenterology 100:520–528, 1991.

193. Mandell MS: Critical care issues: Portopulmonary hypertension. Liver Transpl 6(4 Suppl 1):S36–S43, 2000.

194. Findlay JY, Harrison BA, Plevak DJ, et al: Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension. Liver Transpl Surg 5:381–387, 1999.

195. Mandell MS, Duke J: Nitric oxide reduces pulmonary hypertension during hepatic transplantation. Anesthesiology 81:1538–1542, 1994.

196. Ramsay MA, Schmidt A, Hein HA, et al: Nitric oxide does not reverse pulmonary hypertension associated with end-stage liver disease: A preliminary report. Hepatology 25:524–527, 1997.

197. Ramsay MA, Spikes C, East CA, et al: The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol. Anesthesiology 90:299–301, 1999.

198. Kuo PC, Johnson LB, Plotkin JS, et al: Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 63:604–606, 1997.

199. Moreau R: Hepatorenal syndrome in patients with cirrhosis. J Gastroenterol Hepatol 17:739–747, 2002.

200. Dagher L, Moore K: The hepatorenal syndrome. Gut 49:729–737, 2001.

201. Kramer L, Horl WH: Hepatorenal syndrome. Semin Nephrol 22:290–301, 2002.

202. Moore K: The hepatorenal syndrome. Clin Sci (Lond) 92:433–443, 1997.

203. Davis CL, Gonwa TA, Wilkinson AH: Pathophysiology of renal disease associated with liver disorders: Implications for liver transplantation. Part I. Liver Transpl 8:91–109, 2002.

204. Amitrano L, Guardascione MA, Brancaccio V, et al: Coagulation disorders in liver disease. Semin Liver Dis 22:83–96, 2002.

205. Kang Y: Coagulation and liver transplantation: Current concepts. Liver Transpl Surg 3:465–467, 1997.

206. Kang Y: Coagulopathies in hepatic disease. Liver Transpl 6(4 Suppl 1):S72–S75, 2000.

207. Lisman T, Leebeek FW, de Groot PG: Haemostatic abnormalities in patients with liver disease. J Hepatol 37:280–287, 2002.

208. Baubillier E, Cherqui D, Dominique C, et al: A fatal thrombotic complication during liver transplantation after aprotinin administration. Transplantation 57:1664–1666, 1994.

209. Gologorsky E, De Wolf AM, Scott V, et al: Intracardiac thrombus formation and pulmonary thromboembolism immediately after graft reperfusion in 7 patients undergoing liver transplantation. Liver Transpl 7:783–789, 2001.

210. Prah GN, Lisman SR, Maslow AD, et al: Transesophageal echocardiography reveals an unusual cause of hemodynamic collapse during orthotopic liver transplantation—two case reports. Transplantation 59:921–925, 1995.

211. O'Connor CJ, Roozeboom D, Brown R, et al: Pulmonary thromboembolism during liver transplantation: Possible association with antifibrinolytic drugs and novel treatment options. Anesth Analg 91:296–299, 2000.

212. Fitzsimons MG, Peterfreund RA, Raines DE: Aprotinin administration and pulmonary thromboembolism during orthotopic liver transplantation: Report of two cases. Anesth Analg 92:1418–1421, 2001.

213. Colle IO, Moreau R, Godinho E, et al: Diagnosis of portopulmonary hypertension in candidates for liver transplantation: A prospective study. Hepatology 37:401–409, 2003.

214. Blackwell MM, Chavin KD, Sistino JJ: Perioperative perfusion strategies for optimal fluid management in liver transplant recipients with renal insufficiency. Perfusion 18:55–60, 2003.

215. Avery RK: Recipient screening prior to solid-organ transplantation. Clin Infect Dis 35:1513–1519, 2002.

216. Schumann R: Intraoperative resource utilization in anesthesia for liver transplantation in the United States: A survey. Anesth Analg 97:21–28, 2003.

217. Veroli P, O'Kelly B, Bertrand F, et al: Extrahepatic metabolism of propofol in man during the anhepatic phase of orthotopic liver transplantation. Br J Anaesth 68:183–186, 1992.

218. Raucoules-Aime M, Kaidomar M, Levron JC, et al: Hepatic disposition of alfentanil and sufentanil in patients undergoing orthotopic liver transplantation. Anesth Analg 84:1019–1024, 1997.

219. De Wolf AM, Freeman JA, Scott VL, et al: Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. Br J Anaesth 76:624–628, 1996.

220. O'Kelly B, Jayais P, Veroli P, et al: Dose requirements of vecuronium, pancuronium, and atracurium during orthotopic liver transplantation. Anesth Analg 73:794–798, 1991.

221. Lukin CL, Hein HA, Swygert TH, et al: Duration of vecuronium-induced neuromuscular block as a predictor of liver allograft dysfunction. Anesth Analg 80:526–533, 1995.

222. Gao L, Ramzan I, Baker B: Neuromuscular paralysis as a pharmacodynamic probe to assess organ function during liver transplantation. J Clin Anesth 12:615–620, 2000.

223. Gao L, Ramzan I, Baker B: Rocuronium plasma concentrations during three phases of liver transplantation: Relationship with early postoperative graft liver function. Br J Anaesth 88:764–770, 2002.

224. Gao L, Ramzan I, Baker B: Rocuronium infusion requirements and plasma concentrations at constant levels of neuromuscular paralysis during three phases of liver transplantation. J Clin Anesth 15:257–266, 2003.

225. Shangraw RE, Hexem JG: Glucose and potassium metabolic responses to insulin during liver transplantation. Liver Transpl Surg 2:443–454, 1996.

226. Martin TJ, Kang Y, Robertson KM, et al: Ionization and hemodynamic effects of calcium chloride and calcium gluconate in the absence of hepatic function. Anesthesiology 73:62–65, 1990.

227. Ozier Y, Steib A, Ickx B, et al: Haemostatic disorders during liver transplantation. Eur J Anaesthesiol 18:208–218, 2001.

228. Laine E, Steadman R, Calhoun L, et al: Comparison of RBCs and FFP with whole blood during liver transplant surgery. Transfusion 43:322–327, 2003.

229. Ozier Y, Pessione F, Samain E, et al: Institutional variability in transfusion practice for liver transplantation. Anesth Analg 97:671–679, 2003.

230. Frenette L, Cox J, McArdle P, et al: Conjugated estrogen reduces transfusion and coagulation factor requirements in orthotopic liver transplantation. Anesth Analg 86:1183–1186, 1998.

231. Boylan JF, Klinck JR, Sandler AN, et al: Tranexamic acid reduces blood loss, transfusion requirements, and coagulation factor use in primary orthotopic liver transplantation. Anesthesiology 85:1043–1048, discussion 1030A–1031A, 1996.

232. Dalmau A, Sabate A, Acosta F, et al: Tranexamic acid reduces red cell transfusion better than epsilon-aminocaproic acid or placebo in liver transplantation. Anesth Analg 91:29–34, 2000.

233. Findlay JY, Rettke SR, Ereth MH, et al: Aprotinin reduces red blood cell transfusion in orthotopic liver transplantation: A prospective, randomized, double-blind study. Liver Transpl 7:802–807, 2001.

234. Garcia-Huete L, Domenech P, Sabate A, et al: The prophylactic effect of aprotinin on intraoperative bleeding in liver transplantation: A randomized clinical study. Hepatology 26:1143–1148, 1997.

235. Kaspar M, Ramsay MA. Nguyen AT, et al: Continuous small-dose tranexamic acid reduces fibrinolysis but not transfusion requirements during orthotopic liver transplantation. Anesth Analg 85:281–285, 1997.

236. Marcel RJ, Stegall WC, Suit CT, et al: Continuous small-dose aprotinin controls fibrinolysis during orthotopic liver transplantation. Anesth Analg 82:1122–1125, 1996.

2279

237. Cochran RP, Starkey TD, Panos AL, et al: Ambulatory intraaortic balloon pump use as bridge to heart transplant. Ann Thorac Surg 74:746–751, discussion 751–742, 2002.

238. Bain VG, Montero JL, de La Mata M: Bioartificial liver support. Can J Gastroenterol 15:313–318, 2001.

239. Beavers KL, Sandler RS, Fair JH, et al: The living donor experience: Donor health assessment and outcomes after living donor liver transplantation. Liver Transpl 7:943–947, 2001.

240. Cecka JM: The UNOS Renal Transplant Registry. Clin Transpl 1–20, 2002.

241. Chamuleau RA: Bioartificial liver support anno 2001. Metab Brain Dis 17:485–491, 2002.

242. Hashikura Y, Kawasaki S, Miyagawa S, et al: Recent advance in living donor liver transplantation. World J Surg 26:243–246, 2002.

243. Hendriks HG, Meijer K, de Wolf JT, et al: Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: A pilot study. Transplantation 71:402–405, 2001.

244. Molenaar IQ, Begliomini B, Martinelli G, et al: Reduced need for vasopressors in patients receiving aprotinin during orthotopic liver transplantation. Anesthesiology 94:433–438, 2001.

245. Molenaar IQ, Legnani C, Groenland TH, et al: Aprotinin in orthotopic liver transplantation: Evidence for a prohemostatic, but not a prothrombotic, effect. Liver Transpl 7:896–903, 2001.

246. Porte RJ, Slooff MJ: Aprotinin: Safe and effective in all patients undergoing orthotopic liver transplantation? Liver Transpl 7:808–810, 2001.

247. Stephenson GR, Moretti EW, El-Moalem H, et al: Malnutrition in liver transplant patients: Preoperative subjective global assessment is predictive of outcome after liver transplantation. Transplantation 72:666–670, 2001.

248. Yost CS, Matthay MA, Gropper MA: Etiology of acute pulmonary edema during liver transplantation: A series of cases with analysis of the edema fluid. Chest 119:219–223, 2001.

249. Porte RJ, Molenaar IQ, Begliomini B, et al: Aprotinin and transfusion requirements in orthotopic liver transplantation: A multicentre randomised double-blind study. EMSALT Study Group. Lancet 355:1303–1309, 2000.

250. Murkin JM: A novel hemostatic agent: The potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice. Can J Anaesth 49:S21–S26, 2002.

251. Hedner U, Erhardtsen E: Potential role for rFVIIa in transfusion medicine. Transfusion 42:114–124, 2002.

252. Kalicinski P, Kaminski A, Drewniak T, et al: Quick correction of hemostasis in two patients with fulminant liver failure undergoing liver transplantation by recombinant activated factor VII. Transplant Proc 31:378–379, 1999.

253. Surudo T, Wojcicki M, Milkiewicz P, et al: Rapid correction of prothrombin time after low-dose recombinant factor VIIA in patients undergoing orthotopic liver transplantation. Transplant Proc 35:2323–2325, 2003.

254. Mathur VS: The role of the DA1 receptor agonist fenoldopam in the management of critically ill, transplant, and hypertensive patients. Rev Cardiovasc Med 4(Suppl 1):S35–S40, 2003.

255. Shaw BW Jr, Martin DJ, Marquez JM, et al: Venous bypass in clinical liver transplantation. Ann Surg 200:524–534, 1984.

256. Tisone G, Mercadante E, Dauri M, et al: Surgical versus percutaneous technique for veno-venous bypass during orthotopic liver transplantation: A prospective randomized study. Transplant Proc 31:3162–3163, 1999.

257. Hosein Shokouh-Amiri M, Osama Gaber A, Bagous WA, et al: Choice of surgical technique influences perioperative outcomes in liver transplantation. Ann Surg 231:814–823, 2000.

258. Chari RS, Gan TJ, Robertson KM, et al: Venovenous bypass in adult orthotopic liver transplantation: Routine or selective use? J Am Coll Surg 186:683–690, 1998.

259. Rossi G, Langer M, Maggi U, et al: Veno-venous bypass versus no bypass in orthotopic liver transplantation: Hemodynamic, metabolic, and renal data. Transplant Proc 30:1871–1873, 1998.

260. Schwarz B, Pomaroli A, Hoermann C, et al: Liver transplantation without venovenous bypass: Morbidity and mortality in patients with greater than 50% reduction in cardiac output after vena cava clamping. J Cardiothorac Vasc Anesth 15:460–462, 2001.

261. Parrilla P, Sanchez-Bueno F, Figueras J, et al: Analysis of the complications of the piggy-back technique in 1,112 liver transplants. Transplantation 67:1214–1217, 1999.

262. Aggarwal S, Kang Y, Freeman JA, et al: Postreperfusion syndrome: Cardiovascular collapse following hepatic reperfusion during liver transplantation. Transplant Proc 19(4 Suppl 3):54–55, 1987.

263. Webster NR, Bellamy MC, Lodge JP, et al: Haemodynamics of liver reperfusion: Comparison of two anaesthetic techniques. Br J Anaesth 72:418–421, 1994.

264. Koelzow H, Gedney JA, Baumann J, et al: The effect of methylene blue on the hemodynamic changes during ischemia reperfusion injury in orthotopic liver transplantation. Anesth Analg 94:824–829, 2002.

265. Ayanoglu HO, Ulukaya S, Tokat Y: Causes of postreperfusion syndrome in living or cadaveric donor liver transplantations. Transplant Proc 35:1442–1444, 2003.

266. Acosta F, Sansano T, Contreras RF, et al: Changes in serum potassium during reperfusion in liver transplantation. Transplant Proc 31:2382–2383, 1999.

267. Carmichael FJ, Lindop MJ, Farman JV: Anesthesia for hepatic transplantation: Cardiovascular and metabolic alterations and their management. Anesth Analg 64:108–116, 1985.

268. Nanashima A, Pillay P, Crawford M, et al: Analysis of postrevascularization syndrome after orthotopic liver transplantation: The experience of an Australian liver transplantation center. J Hepatobiliary Pancreat Surg 8:557–563, 2001.

269. Acosta F, Rodriguez MA, Sansano T, et al: Influence of surgical technique on postreperfusion syndrome during liver transplantation. Transplant Proc 31:2380–2381, 1999.

270. Aggarwal S, Kang Y, Freeman JA, et al: Postreperfusion syndrome: Hypotension after reperfusion of the transplanted liver. J Crit Care 8:154–160, 1993.

271. Markmann JF, Markmann JW, Desai NM, et al: Operative parameters that predict the outcomes of hepatic transplantation. J Am Coll Surg 196:566–572, 2003.

272. Mandell MS, Lockrem J, Kelley SD: Immediate tracheal extubation after liver transplantation: Experience of two transplant centers. Anesth Analg 84:249–253, 1997.

273. Glanemann M, Langrehr J, Kaisers U, et al: Postoperative tracheal extubation after orthotopic liver transplantation. Acta Anaesthesiol Scand 45:333–339, 2001.

274. Neelakanta G, Sopher M, Chan S, et al: Early tracheal extubation after liver transplantation. J Cardiothorac Vasc Anesth 11:165–167, 1997.

275. Findlay JY, Jankowski CJ, Vasdev GM, et al: Fast track anesthesia for liver transplantation reduces postoperative ventilation time but not intensive care unit stay. Liver Transpl 8:670–675, 2002.

276. Mandell MS, Lezotte D, Kam I, et al: Reduced use of intensive care after liver transplantation: Patient attributes that determine early transfer to surgical wards. Liver Transpl 8:682–687, 2002.

277. Biancofiore G, Romanelli AM, Bindi ML, et al: Very early tracheal extubation without predetermined criteria in a liver transplant recipient population. Liver Transpl 7:777–782, 2001.

278. Mandell MS, Lezotte D, Kam I, et al: Reduced use of intensive care after liver transplantation: Influence of early extubation. Liver Transpl 8:676–681, 2002.

279. Moretti EW, Robertson KM, Tuttle-Newhall JE, et al: Orthotopic liver transplant patients require less postoperative morphine than do patients undergoing hepatic resection. J Clin Anesth 14:416–420, 2002.

2280

280. Donovan KL, Janicki PK, Striepe VI, et al: Decreased patient analgesic requirements after liver transplantation and associated neuropeptide levels. Transplantation 63:1423–1429, 1997.

281. Eisenach JC, Plevak DJ, Van Dyke RA, et al: Comparison of analgesic requirements after liver transplantation and cholecystectomy. Mayo Clin Proc 64:356–359, 1989.

282. Kato T, Ruiz P, Thompson JF, et al: Intestinal and multivisceral transplantation. World J Surg 26:226–237, 2002.

283. Bellamy MC, Enright SM, Young Y, et al: Living related small bowel transplantation: Anaesthesia and peri-operative care. Eur J Anaesthesiol 14:450–454, 1997.

284. Grover FL, Barr ML, Edwards LB, et al: Thoracic transplantation. Am J Transplant 3(Suppl 4):91–102, 2003.

285. Hertz MI, Taylor DO, Trulock EP, et al: The registry of the International Society for Heart and Lung Transplantation: Nineteenth official report—2002. J Heart Lung Transplant 21:950–970, 2002.

286. Aranda JM Jr, Hill J: Cardiac transplant vasculopathy. Chest 118:1792–1800, 2000.

287. Kobashigawa J: What is the optimal prophylaxis for treatment of cardiac allograft vasculopathy? Curr Control Trials Cardiovasc Med 1:166–171, 2000.

288. Cooper JD, Billingham M, Egan T, et al: A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant 12:713–716, 1993.

289. Mudge GH, Goldstein S, Addonizio LJ, et al: 24th Bethesda conference: Cardiac transplantation. Task Force 3: Recipient guidelines/prioritization. J Am Coll Cardiol 22:21–31, 1993.

290. Baldwin JC, Anderson JL, Boucek MM, et al: 24th Bethesda conference: Cardiac transplantation. Task Force 2: Donor guidelines. J Am Coll Cardiol 22:15–20, 1993.

291. Miniati DN, Robbins RC: Heart transplantation: A thirty-year perspective. Annu Rev Med 53:189–205, 2002.

292. Chen JM, Sinha P, Rajasinghe HA, et al: Do donor characteristics really matter? Short- and long-term impact of donor characteristics on recipient survival, 1995–1999. J Heart Lung Transplant 21:608–610, 2002.

293. Brock MV, Salazar JD, Cameron DE, et al: The changing profile of the cardiac donor. J Heart Lung Transplant 20:1005–1009, 2001.

294. Marelli D, Laks H, Kobashigawa JA, et al: Seventeen-year experience with 1,083 heart transplants at a single institution. Ann Thorac Surg 74:1558–1566, discussion 1567, 2002.

295. Jacobbi LM, McBride V, Like K, et al: Increasing the donor pool: Recovery of hearts from older donors. Transplant Proc 29:3297–3298, 1997.

296. Young JB: Cardiac transplantation: Three decades of experience define our challenge. Transplant Proc 30:1885–1888, 1998.

297. Spann JC, Van Meter C: Cardiac transplantation. Surg Clin North Am 78:679–690, 1998.

298. Cimato TR, Jessup M: Recipient selection in cardiac transplantation: Contraindications and risk factors for mortality. J Heart Lung Transplant 21:1161–1173, 2002.

299. Macoviak JA: The perioperative and surgical aspects of heart transplantation. Cardiol Clin 8:73–82, 1990.

300. Griepp RB, Stinson EB, Dong E Jr, et al: Determinants of operative risk in human heart transplantation. Am J Surg 122:192–197, 1971.